

# Supplementary Materials: SUPPLEMENTARY FILE S4: CODE REPOSITORY

## Supplementary File S4

### Code Repository

Configuration

Version 2.1 | October 2025

DOI: <https://doi.org/10.5281/zenodo.17873201>

*Corresponding manuscript:* Demidont, A.C. (2025). Computational Validation of a Clinical Decision Support Algorithm for LAI-PrEP Bridge Period Navigation. *Viruses*.

### Overview

This supplementary file documents the complete software implementation, validation datasets, test suites, and reproducibility protocols for the LAI-PrEP Bridge Period Decision Support Tool. All materials are publicly available under MIT License to enable widespread implementation, independent validation, and continuous improvement.

### Repository Information

- **Primary Repository:** GitHub Repository: <https://github.com/Nyx-Dynamics/lai-prep-bridge-tool-pub>
- **Persistent Archive:** Zenodo DOI: <https://doi.org/10.5281/zenodo.17873201>
- **License:** MIT License (open source)
- **Version:** 2.1.0 (manuscript validation version)
- **Language:** Python 3.8+
- **Dependencies:** NumPy (optional), minimal external requirements

### 1. Repository Contents

#### 1.1. Core Implementation Files

##### 1.1.1. 1. Main Decision Algorithm

**File:** lai\_prep\_decision\_tool\_v2\_1.py

**Description:** Core decision support algorithm implementing:

- Patient risk stratification
- Barrier assessment (13 categories)
- Population-specific baseline rates (7 populations)
- Evidence-based intervention recommendations (21 interventions)
- Mechanism diversity scoring
- Outcome prediction calculations

**Key Classes:**

- Population (Enum): MSM, cisgender women, transgender women, adolescents, PWID, pregnant/lactating, general
- Barrier (Enum): 13 structural/social/clinical barriers

- `Intervention` (Enum): 21 evidence-based interventions 36
  - `HealthcareSetting` (Enum): 8 clinical settings 37
  - `PatientProfile` (Dataclass): Patient characteristics 38
  - `BridgeAssessment` (Dataclass): Risk assessment output 39
  - `LAIPrEPDecisionTool` (Class): Core decision algorithm 40
- Lines of Code:** 850 lines **Validation Status:** 100% test pass rate (18/18 edge cases) 41

#### 1.1.2. 2. External Configuration 42

**File:** `lai_prep_config_FIXED.json` 43

**Description:** Machine-readable configuration enabling parameter updates without code changes. Contains: 44

- Population-specific baseline success rates with confidence intervals 46
- Barrier prevalence by population (13 barriers × 7 populations) 47
- Intervention effect sizes with evidence levels (21 interventions) 48
- Mechanism diversity classifications 49
- Implementation complexity ratings 50
- Cost estimates (where available) 51

**Size:** ~25 KB JSON **Purpose:** Enables local adaptation, evidence updates, transparency 52

##### **Key Sections:** 54

- `population_baselines`: Success rates by population 55
- `barrier_prevalence`: Barrier rates by population 56
- `interventions`: Complete intervention library 57
- `mechanisms`: Diversity scoring categories 58

#### 1.1.3. 3. Command-Line Interface 59

**File:** `cli.py` 60

**Description:** User-friendly command-line interface for: 61

- Single patient assessments 62
- Batch processing from CSV 63
- JSON input/output for EHR integration 64
- Validation dataset generation 65
- Results export and reporting 66

##### **Example Usage:** 67

*# Assess single patient* 68

```
python cli.py assess -i example_patient.json -o results.json
```

 69

*# Batch processing* 71

```
python cli.py batch -i patients.csv -o results_batch.csv
```

 72

*# Generate validation dataset* 74

```
python cli.py validate -n 1000000 -o validation_1M.json
```

 75

#### 1.2. Test Suites 76

##### 1.2.1. 4. Edge Case Testing 77

**File:** `test_edge_cases.py` 78

**Description:** Comprehensive edge case testing (18 test scenarios): 79

1. **Oral PrEP advantage:** Verifies oral→injectable transitions have higher success 80

2. **Barrier impact:** Confirms barriers reduce success rate 81
3. **Population differences:** Validates population-specific baselines 82
4. **Intervention effectiveness:** Ensures interventions improve outcomes 83
5. **Extreme barriers:** Tests 5+ barrier combinations 84
6. **No barriers:** Validates high-success scenarios 85
7. **PWID harm reduction:** Confirms SSP integration critical for PWID 86
8. **Adolescent navigation:** Tests youth-specific requirements 87
9. **Insurance delays:** Validates authorization barrier impact 88
10. **Multiple populations:** Tests overlapping categories 89
11. **Same-day switching:** Verifies immediate initiation protocol 90
12. **Mechanism diversity:** Ensures non-redundant recommendations 91
13. **Configuration loading:** Tests external JSON parsing 92
14. **Boundary conditions:** 0% and 100% success scenarios 93
15. **Missing data:** Handles incomplete patient profiles 94
16. **Invalid inputs:** Graceful error handling 95
17. **Reproducibility:** Consistent results across runs 96
18. **Performance:** <30 seconds per patient assessment 97

**Test Pass Rate:** 18/18 (100%) **Framework:** Python pytest 98

#### 1.2.2. 5. Unit Testing 99

**Files:** test\_suite.py, test\_suite\_2.py, test\_suite\_3.py, test\_suite\_4.py 100

**Description:** Progressive test suite development: 101

- test\_suite.py: Initial validation framework 102
- test\_suite\_2.py: Population-specific tests 103
- test\_suite\_3.py: Intervention effectiveness tests 104
- test\_suite\_4.py: Integration and performance tests 105

**Coverage:** 106

- Unit tests: Individual function validation 107
- Integration tests: End-to-end workflow 108
- Population tests: 1,000-patient synthetic validation 109
- Performance tests: Scalability verification 110

#### 1.2.3. 6. Configuration Validation 111

**File:** validate\_config.py 112

**Description:** Validates external JSON configuration: 113

- Schema compliance 114
- Parameter ranges (0-1 for probabilities) 115
- Evidence level consistency 116
- Intervention-barrier mappings 117
- Mechanism classification completeness 118

## 2. Validation Datasets 119

Three progressive validation tiers demonstrating convergence and precision: 120

### 2.1. Tier 2: 1 Million Patient Validation 121

**File:** validation\_1M\_results.json 122

**Key Findings:** 123

- **Sample size:** 1,000,000 patients 124
- **Mean baseline success:** 27.7% (95% CI: 27.6–27.8%) 125

- **Margin of error:**  $\pm 0.09$  percentage points
- **Mean improvement:** +19.2 percentage points with interventions
- **Runtime:** 92 seconds ( $\sim 10,870$  patients/second)

#### **By Population:**

- MSM: 37.7% baseline
- General: 35.7% baseline
- Transgender women: 32.8% baseline
- Cisgender women: 28.1% baseline
- Pregnant/lactating: 28.0% baseline
- Adolescents: 19.4% baseline
- PWID: 12.2% baseline

### *2.2. Tier 3: 10 Million Patient Validation*

**File:** validation\_10M\_results.json

#### **Key Findings:**

- **Sample size:** 10,000,000 patients
- **Mean baseline success:** 27.7% (95% CI: 27.67–27.73%)
- **Margin of error:**  $\pm 0.028$  percentage points
- **Mean improvement:** +19.2 percentage points
- **Mean with interventions:** 46.9%
- **Runtime:** 102 seconds ( $\sim 98,040$  patients/second)
- **Precision improvement:** 3.2 $\times$  better than 1M validation

#### **Healthcare Setting Analysis:**

- Academic medical center: 27.7%
- Community health center: 27.7%
- Private practice: 27.7%
- Pharmacy-based: 27.7%
- LGBTQ center: 27.7%
- Harm reduction/SSP: 27.7%
- Mobile clinic: 27.7%
- Telehealth-integrated: 27.7%

*Note: Minimal setting variation validates focus on population/barriers rather than facility type.*

### *2.3. Tier 4: 21.2 Million Patient UNAIDS Global Scale*

**File:** validation\_UNAIDS\_21\_2M\_results.json

#### **Key Findings:**

- **Sample size:** 21,200,000 patients (UNAIDS 2025 target)
- **Mean baseline success:** 23.96% (95% CI: 23.94–23.98%)
- **Margin of error:**  $\pm 0.018$  percentage points (policy-grade precision)
- **Mean improvement:** +19.5 percentage points
- **Mean with interventions:** 43.5%
- **Additional successful transitions:** 4.14 million globally
- **Runtime:** 253 seconds ( $\sim 83,800$  patients/second)
- **Precision improvement:** 5.1 $\times$  better than 10M validation

#### **Regional Disparities:**

- **Europe/Central Asia:** 29.3% baseline (highest)
- **North America:** 29.3% baseline

- **Asia-Pacific:** 24.8% baseline 172
- **Latin America/Caribbean:** 24.8% baseline 173
- **Sub-Saharan Africa:** 21.7% baseline (lowest, serves 62% of patients) 174
- **Equity Gap:** 7.6 percentage points between highest and lowest regions 175
- **Population Disparities:** 176
- **MSM:** 33.1% baseline (highest) 177
- **General:** 31.2% baseline 178
- **Transgender women:** 28.5% baseline 179
- **Pregnant/lactating:** 24.1% baseline 180
- **Cisgender women:** 24.1% baseline 181
- **Adolescents:** 16.3% baseline 182
- **PWID:** 10.4% baseline (lowest) 183
- **Equity Gap:** 22.7 percentage points between MSM and PWID 184

### 3. Documentation Files 185

#### 3.1. Supporting Documentation 186

1. **README.md:** Installation, quick start, usage examples 187
2. **CHANGELOG.md:** Version history, release notes 188
3. **requirements.txt:** Production dependencies 189
4. **requirements-dev.txt:** Development/testing dependencies 190
5. **example\_patient.json:** Sample patient profile with valid values 191
6. **example\_patients.csv:** Batch processing example 192

#### 3.2. Analysis Documentation 193

1. **VALIDATION\_RESULTS.md:** Comprehensive validation summary 194
2. **UNAIDS\_Validation\_Analysis.md:** Global-scale validation analysis 195

### 4. Reproducibility Protocol 196

#### 4.1. System Requirements 197

- **Operating System:** Windows, macOS, Linux 198
- **Python Version:** 3.8 or higher 199
- **RAM:** 4 GB minimum, 8 GB recommended for large validations 200
- **Storage:** 100 MB for code/data, 1 GB for validation datasets 201
- **Processor:** Modern CPU (2+ GHz recommended) 202

#### 4.2. Installation Instructions 203

##### # Clone repository 204

```
git clone https://github.com/[repository-url]
```

```
cd lai-prep-bridge-tool
```

##### # Create virtual environment (recommended) 208

```
python -m venv venv
```

```
source venv/bin/activate # On Windows: venv\Scripts\activate
```

##### # Install dependencies 212

```
pip install -r requirements.txt
```

##### # Run tests to verify installation 215

```
pytest test_edge_cases.py -v
```

#### 4.3. Validation Reproduction

##### Reproduce 1M validation:

```
python cli.py validate -n 1000000 -o my_validation_1M.json
```

##### Reproduce 10M validation:

```
python cli.py validate -n 10000000 -o my_validation_10M.json
```

##### Reproduce 21.2M UNAIDS validation:

```
python cli.py validate -n 21200000 --unaids -o my_validation_UNAIDS.json
```

##### Compare results:

```
import json
```

```
# Load original and reproduction results
```

```
with open('validation_1M_results.json') as f:
```

```
    original = json.load(f)
```

```
with open('my_validation_1M.json') as f:
```

```
    reproduction = json.load(f)
```

```
# Compare key metrics
```

```
print(f"Original:_{original['avg_success_rate']:.4f}")
```

```
print(f"Reproduction:_{reproduction['avg_success_rate']:.4f}")
```

```
print(f"Difference:_{abs(original['avg_success_rate'] -  
reproduction['avg_success_rate']):.6f}")
```

**Expected Variability:** Due to random patient generation, reproductions should match within  $\pm 0.001$  (0.1 percentage points) for 1M+ samples.

#### 4.4. Local Adaptation

##### Modify parameters for local context:

1. Open lai\_prep\_config\_FIXED.json
2. Update relevant parameters:
  - Barrier prevalence rates
  - Intervention effect sizes
  - Population baseline rates
  - Available interventions
3. Validate changes: python validate\_config.py
4. Test with local data: python cli.py assess -i local\_patients.csv

##### Example parameter modification:

```
{
  "interventions" {
    "PATIENT_NAVIGATION" {
      "improvement" 0.15, // Change from 0.12 to 0.15
      "evidence_level" "strong",
      "evidence_source" "Local_pilot_study_2025"
    }
  }
}
```

5. Data Privacy and Security

5.1. Synthetic Data Only

**CRITICAL:** All validation datasets contain **synthetic patients only**. No real patient data included.

- Patients generated using random distributions
- Demographics and barriers assigned probabilistically
- No PHI (Protected Health Information)
- Safe for public repository
- HIPAA compliance not applicable (synthetic data)

5.2. Implementation Privacy Guidelines

For real-world implementation with actual patients:

1. **De-identification:** Remove all 18 HIPAA identifiers before data export
2. **Local storage:** Keep patient data on secure local systems
3. **Encrypted transmission:** Use HTTPS/TLS for any data transfer
4. **Access control:** Limit tool access to authorized clinicians
5. **Audit logging:** Track who accessed patient assessments when
6. **Data retention:** Follow institutional policies for PHI retention
7. **IRB approval:** Obtain institutional review for outcome tracking

5.3. Ethical Considerations

- **Algorithmic transparency:** All calculations visible and explainable
- **Clinical override:** Tool supports, does not replace, clinical judgment
- **Bias monitoring:** Track outcomes across populations for fairness
- **Continuous improvement:** Update parameters as evidence evolves
- **Equity focus:** Prioritize closing disparities, not widening them

6. Code Quality and Testing

6.1. Code Quality Metrics

- **Lines of Code:** 850 (core algorithm)
- **Test Coverage:** 100% (18/18 edge cases pass)
- **Documentation:** Comprehensive inline comments
- **Type Hints:** Full type annotations (Python 3.8+)
- **Code Style:** PEP 8 compliant
- **Complexity:** Low cyclomatic complexity

6.2. Performance Benchmarks

| Test Size  | Runtime | Patients/sec | Memory  |
|------------|---------|--------------|---------|
| 1,000      | <1 sec  | ~1,000       | <100 MB |
| 1,000,000  | 92 sec  | ~10,870      | <2 GB   |
| 10,000,000 | 102 sec | ~98,040      | <4 GB   |
| 21,200,000 | 253 sec | ~83,800      | <4 GB   |

**Streaming Architecture:** Processes patients one-at-a-time, enabling million-scale validation with minimal RAM.

6.3. Continuous Integration

Recommended CI/CD pipeline:

1. **Automated testing:** Run test suite on every commit

|  |  |                   |
|--|--|-------------------|
| 2.   | <b>Code quality:</b> Lint with flake8, format with black               | 299               |
| 3.   | <b>Type checking:</b> Validate with mypy                               | 300               |
| 4.   | <b>Performance:</b> Benchmark regression tests                         | 301               |
| 5.   | <b>Documentation:</b> Build Sphinx docs automatically                  | 302               |
| <b>7. Future Development Roadmap</b>   |  | 303               |
| 7.1. <i>Planned Features</i>   |  | 304               |
| <b>Version 1.1 (Q1 2026):</b>  |  | 305               |
| •  | EHR integration modules (Epic, Cerner FHIR APIs)                       | 306               |
| •  | Real-time outcome tracking dashboard                                   | 307               |
| •  | Multi-language support (Spanish, French)                               | 308               |
| •  | Improved web interface   | 309               |
| <b>Version 1.2 (Q2 2026):</b>  |  | 310               |
| •  | Machine learning enhancements for barrier detection                    | 311               |
| •  | Synergistic intervention modeling (beyond additive)                    | 312               |
| •  | Time-to-event prediction (not just initiation success)                 | 313               |
| •  | Mobile application (iOS/Android)                                       | 314               |
| <b>Version 2.0 (Q3 2026):</b>  |  | 315               |
| •  | PURPOSE-3/4 trial data integration                                     | 316               |
| •  | HPTN 102/103 evidence updates  | 317               |
| •  | International adaptation frameworks                                    | 318               |
| •  | Cost-effectiveness module  | 319               |
| 7.2. <i>Research Priorities</i>  |  | 320               |
| 1.   | <b>Prospective validation:</b> Real-world patient outcome studies      | 321               |
| 2.   | <b>Calibration studies:</b> Compare predicted vs. actual rates         | 322               |
| 3.   | <b>Equity analyses:</b> Subgroup performance evaluation                | 323               |
| 4.   | <b>Implementation trials:</b> Systematic navigation vs. standard care  | 324               |
| 5.   | <b>Cost-effectiveness:</b> Economic evaluation of intervention bundles | 325               |
| <b>8. Contributing and Support</b>   |  | 326               |
| 8.1. <i>How to Contribute</i>  |  | 327               |
| 1.   | <b>Report issues:</b> GitHub Issues tracker                            | 328               |
| 2.   | <b>Suggest features:</b> Feature request template                      | 329               |
| 3.   | <b>Submit evidence updates:</b> New trial results, implementation data | 330               |
| 4.   | <b>Code contributions:</b> Pull requests with tests                    | 331               |
| 5.   | <b>Documentation:</b> Improve guides, add examples                     | 332               |
| 8.2. <i>Citation</i>   |  | 333               |
| When using this tool in research or implementation:  |  | 334               |
| <b>Primary Citation:</b>   |  | 335               |
| Demidont, A.C Computational Validation of a Clinical Decision Support Algorithm for Long-Acting Injectable PrEP Bridge Period Navigation at UNAIDS Global Target Scale. <i>Viruses</i> <b>2025</b> , XX, XXX.                              |  | 336<br>337<br>338 |
| <b>Software Citation:</b>  |  | 339               |
| Demidont, A.C LAI-PrEP Bridge Period Decision Support Tool (Version 2.1.0) [Software]. GitHub Respository: <a href="https://github.com/Nyx-Dynamics/lai-prep-bridge-tool-pub">https://github.com/Nyx-Dynamics/lai-prep-bridge-tool-pub</a> |  | 340<br>341<br>342 |



8.3. Support Resources343

GitHub Repository<https://github.com/Nyx-Dynamics/lai-prep-bridge-tool-pub> Zen-344  
dodo doi<https://doi.org/10.5281/zenodo.17873201> Email: [acdemidont@nyxdynamics.org](mailto:acdemidont@nyxdynamics.org)345

9. License346

This software is released under the MIT License:347

Copyright (c) 2025 A.C Demidont, DO348

Permission is hereby granted, free of charge, to any person obtaining a copy of this349  
software and associated documentation files (the "Software"), to deal in the Software350  
without restriction, including without limitation the rights to use, copy, modify, merge,351  
publish, distribute, sublicense, and/or sell copies of the Software, and to permit persons to352  
whom the Software is furnished to do so, subject to the following conditions:353

The above copyright notice and this permission notice shall be included in all copies or354  
substantial portions of the Software.355

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EX-356  
PRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MER-357  
CHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT.358  
IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY359  
CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT,360  
TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION WITH THE361  
SOFTWARE OR THE USE OR OTHER DEALINGS IN THE SOFTWARE.362

10. Acknowledgments363

- This work builds upon:364
- HPTN 083, 084, PURPOSE-1, PURPOSE-2 clinical trial data365
  - Real-world implementation studies from multiple clinical sites366
  - Patient navigation literature from cancer care and HIV prevention367
  - UNAIDS global HIV prevention targets and monitoring frameworks368
  - WHO consolidated guidelines on HIV prevention services369

Reference: A.C Demidont, DO(2025). Computational Validation of a Clinical Decision370  
Support Algorithm for Long-Acting Injectable PrEP Bridge Period Navigation at UNAIDS371  
Global Target Scale. *Viruses*.372

Repository Version: 2.1.0 (manuscript validation version) Last Updated: December373  
9, 2025374